ESCC Clinical Trial
Official title:
An Exploratory Study of the Efficacy and Safety of DCF Regimen Combined With Camrelizumab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma(ESCC)
To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC
Primary outcome: To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC Secondary outcome: pathologic complete response (pCR)、Major Pathologic Response（MPR）、R0 resection rate、Objective response rate（ORR）、Disease free survival（DFS）、Relief rate and safety of dysphagia ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04471480 -
TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer
|
N/A | |
| Recruiting |
NCT04686682 -
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04863079 -
Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )
|
Phase 2 | |
| Completed |
NCT04939701 -
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05547828 -
Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma
|
Phase 2 |